News Headlines Article

A step closer to a cure: Gilead seeks FDA OK of oral attack on hepatitis C
San Francisco Business Times

Gilead Sciences Inc. asked U.S. regulators Monday to approve what could be the first oral treatment for most hepatitis C patients. The Foster City-based drug developer (NASDAQ: GILD) submitted a new drug application to the Food and Drug Administration for a once-a-day combination of the experimental drug ledipasvir and Sovaldi in patients with genotype 1 hepatitis C.